Open AccessAntiviral activity of doxycycline against vesicular stomatitis virusin vitro
Author(s) -
Zhuanchang Wu,
Xin Wang,
Jianchao Wei,
Beibei Li,
Donghua Shao,
Yuming Li,
Ke Liu,
Yuanyuan Shi,
Bin Zhou,
Yafeng Qiu,
Zhiyong Ma
Publication year - 2015
Publication title -
fems microbiology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 151
eISSN - 1574-6968
pISSN - 0378-1097
DOI - 10.1093/femsle/fnv195
Subject(s) - vesicular stomatitis virus , doxycycline , cytopathic effect , infectivity , virology , biology , microbiology and biotechnology , virus , in vitro , viral replication , vesicular stomatitis indiana virus , effector , vesicular stomatitis , coxsackievirus , tetracycline , rhabdoviridae , antibiotics , immunology , enterovirus , biochemistry
Doxycycline (Dox) is a tetracycline derivative with broad-spectrum antimicrobial activities that is used as an effector substance in inducible gene-expression systems. We investigated the antiviral activity of Dox against vesicular stomatitis virus (VSV) infection in cultured H1299 cells. Dox at concentrations of 1.0-2.0 μg ml(-1) significantly inhibited VSV replication and the VSV-induced cytopathic effect in dose-dependent manners, suggesting that Dox may have broader activity in inhibiting viral replication, in addition to its well-defined bacteriostatic activity. Dox exerted its antiviral effect at the early-mid stage of VSV infection, suggesting that it did not interfere with VSV infectivity, adsorption, or entry into target cells. These results indicate that Dox can inhibit VSV infection and may therefore have potential applications for the treatment of viral infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom